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Abstract 
The development of nano-materials is viewed as one of the most important technological advances of the 21st 
century and new applications of nano-sized particles in the production, processing, packaging or storage of food are 
expected to emerge soon. This trend of growing commercialization of engineered nano-particles as part of modern 
diet will substantially increase oral exposure. Contrary to the proven benefits of nano-materials, however, possible 
adverse health effects have generally received less attention. This problem is very well illustrated by nano-structured 
synthetic amorphous silica (SAS), which is a common food additive since several decades although the relevant risk 
assessment has never been satisfactorily completed. A no observed adverse effect level of 2500 mg SAS particles/kg  
body weight per day was derived from the only available long-term administration study in rodents. However, 
extrapolation to a safe daily intake for humans is problematic due to limitations of this chronic animal study and 
knowledge gaps as to possible local intestinal effects of SAS particles, primarily on the gut-associated lymphoid 
system. This uncertainty is aggravated by digestion experiments indicating that dietary SAS particles preserve their 
nano-sized structure when reaching the intestinal lumen. An important aspect is whether food-borne particles like 
SAS alter the function of dendritic cells that, embedded in the intestinal mucosa, act as first-line sentinels of foreign 
materials. We conclude that nano-particles do not represent a completely new threat and that most potential risks 
can be assessed following procedures established for conventional chemical hazards. However, specific properties of 
food-borne nano-particles should be further examined and, for that purpose, in vitro tests with decision-making cells 
of the immune system are needed to complement existing in vivo studies.
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Background
The use of nanotechnology has many potentially ben-
eficial applications in food production, processing and 
storage. The largest share of predicted markets involves 
nano-sized coatings of food-packaging materials that 
optimize mechanical properties or exert antimicro-
bial activity. In the future, nano-sized additives may be 
deliberately included to modify food properties such as 
taste, sensation, color, texture, consistency or shelf life, 
to fortify basic foods with nutrients and vitamins or to 
enhance bioavailability. An emerging application in the 
food industry includes, for example, the use of nano-Fe 
particles for iron supplementation. Nano-sized mate-
rials might further be employed as indicators of food 
quality and freshness, or to ensure traceability [1–3]. In 
contrast to these novel developments, nano-structured 
silica has been on the market as a food additive since 
around 50 years. In the United States, the Food and Drug 
Administration allows up to 2 % by weight of such silica 
particles to be added to food [4]. Within the European 
Union (EU), Commission Regulation 1129/2011 sets a 
maximum level for silica of 1 % by weight in dried pow-
dered foodstuffs [5]. Silica particles may thus be regarded 
as a paradigmatic case for the safety assessment of nano-
material applications in the food industry.
A European Commission Recommendation defines 
nano-materials as having one dimension not exceeding 
100 nm [6]. However, there is no solid scientific ground 
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to propose a strict size boundary and the prefix “nano” 
does not make a substance automatically harmful. Nev-
ertheless, the nano-size scale changes the material char-
acteristics as compared to larger particles or the same 
substance in a dissolved state. Nano-sized materials dis-
play an increased surface-to-mass ratio that enhances 
their reactivity compared to larger structures [7, 8]. Also, 
nano-sized particles easily penetrate intact cell mem-
branes thus conferring the potential for trafficking across 
biological barriers including the epithelium of the gas-
trointestinal tract [9–13]. Until now, the health effects of 
nano-particles have been studied mainly in relation to a 
respiratory uptake [14]. Considering their widespread 
food-related uses, however, there is an urgent need to 
review the suitability of oral toxicity and risk assessment 
studies addressing the long-term safety of nano-struc-
tured silica.
Synthetic amorphous silica
Silicon (Si) is a metalloid displaying an atomic weight 
of 28. The terms “silicium” and “silica” refer to naturally 
occurring or anthropogenic materials composed of sili-
con dioxide (SiO2), which appears in two major forms, 
i.e., crystalline and amorphous. Synthetic amorphous 
silica (SAS) is widely applied to processed foods and 
registered by the EU as a food additive with the code 
E 551 [15]. The main purpose of SAS particles in the food 
industry is to prevent poor flow or “caking”, particularly 
in powdered products. SAS particles are additionally 
employed as a thickener in pastes or as a carrier of fla-
vors, and also to clarify beverages and control foaming 
[16–18].
Silica particles exist in large amounts in nature and it 
is acknowledged that that they have been dietary con-
stituents throughout human evolution. However, the risk 
assessment of silica discussed in this review is limited 
to man-made materials introduced as food additives. In 
1942, Harry Kloepfer (a chemist working at Degussa, now 
Evonik) invented the Aerosil procedure for the produc-
tion of SAS particles intended for the food industry [19, 
20]. Following a standard pyrogenic process, also known 
as flame hydrolysis, silicon tetrachloride is burned in a 
hydrogen flame at temperatures of 1000–2500  °C, gen-
erating silica nano-particles with a diameter of ~10  nm 
[21]. This material is denoted pyrogenic or fumed silica 
referring to the above production method. In an alterna-
tive wet route of synthesis, nanostructured SAS parti-
cles denoted as precipitated silica, silica gel or hydrous 
silica, are produced from alkali metal silicates dissolved 
in water and reacted with sulphuric acid. In the EU, only 
synthetic particles obtained by these pyrogenic or wet 
processes are allowed as food additive [15]. All SAS prod-
ucts aggregate into larger particles with sizes in the order 
of 100  nm, which further agglomerate to form micron-
sized structures [14, 22]. The term “aggregate” describes 
an assembly of particles held together by strong forces 
such as covalent or metallic bonds. “Agglomerates” of 
particles appear as a consequence of weak forces like van 
der Waals interactions, hydrogen bonding, electrostatic 
attractions or adhesion by surface tensions. SAS mate-
rials are hydrophilic but can be rendered hydrophobic, 
thus reducing their moisture uptake, by subsequent sur-
face modifications.
Oral toxicity studies using SAS particles
A synopsis of animal studies addressing the oral safety of 
SAS particles was published by the European Centre for 
Ecotoxicology and Toxicology of Chemicals (ECETOC) 
[23] and, more recently, by the Organization for Eco-
nomic Co-operation and Development (OECD) [24]. No 
mortality or adverse signs resulted from acute exposure 
by single oral administrations of hydrophilic SAS par-
ticles to rodents at doses of up to 5000 mg per kg body 
weight. A sub-acute (28-day) study was carried out by 
oral gavage administration of hydrophilic SAS particles 
to Wistar rats. The daily doses ranged between 100 and 
1000  mg/kg body weight. None of the monitored end-
points (clinical signs, food consumption, body weight, 
behavioral tests, hematology, clinical chemistry param-
eters, organ weights, macroscopic pathology and his-
tological examinations) revealed any substance-related 
abnormalities [25].
In a sub-chronic (90-day) toxicity study carried out in 
Charles River rats with daily doses of up to 3500 mg/kg 
body weight, hydrophilic SAS particles included in the 
feed did not elicit systemic toxicity and did not affect 
growth rate, food consumption or survival [26]. Also, no 
macroscopic or microscopic changes were observed in 
post-mortem analyses of the organs of exposed animals. 
A more detailed 90-day toxicity study was conducted in 
Wister rats with in-diet administrations of hydrophilic 
SAS particles (up to 4000 mg/kg body weight daily). End-
points included general condition and survival, behavior, 
water intake, food consumption, body weight, hematol-
ogy, clinical chemistry, urinary analysis, organ weights, 
macroscopic pathology and histological examinations. 
As observed in the previous sub-chronic study, none of 
these parameters revealed any effects ascribed to SAS 
ingestion [27]. Sub-chronic dietary exposure studies were 
also carried out with hydrophobic SAS particles not per-
mitted as food additive in the EU. In one case [28], no 
treatment-related abnormalities were reported except 
minimal changes in the thyroid gland morphology of 
male rats exposed to 2000 and 4000 mg/kg body weight 
daily. In another repeated dose toxicity study with hydro-
phobic SAS particles [29, 30], Wister rats were exposed 
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via the diet for 5  weeks at 0 (control), 500 or 1000   
mg/kg body weight per day, and for 8 weeks at progres-
sively increasing SAS doses from 2000 to 16,000  mg/kg 
body weight per day. Animals in these high-dose group 
developed severe atrophy of the liver detected by micro-
scopic examination, which was also observed to a milder 
degree in the 1000-mg/kg dose group.
Further effects on the liver were described in more 
recent reports, thus converging on a potential systemic 
hazard of SAS particles (Table  1). In one repeated oral 
toxicity study, BALB/c mice were exposed for 10  weeks 
to hydrophilic nano- or micron-sized silica particles 
prepared from rice husk (not permitted as food additive 
in the EU) [31]. The inclusion rate in feed was 1 % (wt/
wt) translating to an expected oral uptake of 1500  mg/
kg body weight per day. The animal group fed the nano-
particles showed a significantly higher serum level of 
alanine aminotransferase (a biomarker of liver injury) 
compared to untreated controls or animals tested with 
micro-sized silica. In the histologic examination of tis-
sues from mice exposed to nano-particles, but not in 
those exposed to micro-particles, there was an appear-
ance of fatty liver characterized by abnormally frequent 
lipid droplets in hepatocytes. Further liver reactions were 
detected in a repeated dose toxicity study in Sprague–
Dawley rats [32]. The animals were exposed via feed to 
hydrophilic SAS particles obtained from Evonik (denoted 
“Evonik-SAS”) or from the Joint Research Centre of the 
European Commission (denoted “JRC-SAS”). Both mate-
rials were produced by flame hydrolysis but differed in 
their surface area, i.e., 380 and 200 m2/g for “Evonik-SAS” 
and “JRC-SAS”, respectively. These particles were deliv-
ered with the feed at different daily doses (between 100 
and 2500  mg/kg body weight) for 28  days, whereby the 
exposure was extended to 84  days for the highest dose 
groups. No treatment-related effects were observed after 
28  days. However, following 84  days of exposure, the 
occurrence of periportal liver fibrosis was higher than in 
control animals (Table 1). This increase in the frequency 
of liver fibrosis was significant in the JRC-SAS-treated 
animals (p  =  0.02) but slightly below statistical signifi-
cance (p  =  0.07) in the Evonik-SAS-treated group. The 
histological effects were not accompanied by changes in 
clinical chemistry. Notably, this experiment also included 
some immunological parameters like IgG and IgM levels 
in blood, lymphocyte proliferation, as well as cytokine 
release from in vitro activated lymphocytes. None of the 
tested immunological endpoints were affected in any of 
the dose groups.
Long-term dietary studies in rats [33] were used for 
the risk assessment of human exposure. Groups of 40 
Fischer rats were fed 0 (control), 1.25, 2.5 and 5 % (wt/wt) 
hydrophilic SAS particles for 103 consecutive weeks. The 
design of this chronic bioassay is outlined for the high-
dose group in Table  2. The feed was not examined for 
possible nutritional imbalances [34]. There were no test 
substance-related effects on food consumption, overall 
survival, clinical laboratory or hematologic results and 
microscopic pathology findings. Liver weights were sig-
nificantly reduced in the females fed 2.5 and 5 % SAS par-
ticles and this effect might be a consequence of the lower 
body weight attained in these two higher dose groups 
relative to controls and animals in the 1.25  % inclusion 
group. It is retrospectively not possible to distinguish 
whether the effect on liver weight represents an adverse 
reaction to SAS ingestion or whether it is an indirect 
consequence of a possible nutritional imbalance not 
directly related to SAS exposure. Notably, SAS-treated 
males displayed isolated cases of hyperplastic nodules in 
the liver and pheochromcytomas in the adrenal gland, 
but none of the control animals had such rare lesions. 
A long-term study in B6C3F1 mice involved groups 
of 40 animals fed 0 (control), 1.25, 2.5 and 5  % (wt/wt) 
SAS particles for 93 weeks [33]. Again, the feed was not 
examined for nutritional imbalances. The growth rate 
was significantly reduced in the mice of the high-dose 
group only at the end of the first 10 study weeks. Food 
consumption was significantly increased in the males fed 
2.5 and 5 % SAS particles but no other substance-related 
differences came to light. The treatment had no effect on 
clinical chemistry, hematologic results and macroscopic 
as well as microscopic pathology findings. Recently, the 
European Commission Scientific Committee on Con-
sumer Safety pointed out that these long-term studies 
Table 1 Oral repeated dose toxicity studies with amorphous silica yielding liver effects
Delivery of particles was by inclusion into the feed. This table proposes LOAEL (lowest observed adverse effect level) and NOAEL (no observed adverse effect level) 
values that differ from those purported in previous risk assessment reports. Other oral repeated dose studies [25–27] did not elicit adverse effects
Species Study length Effect LOAEL NOAEL Reference
Wistar rats 5–8 weeks Liver atrophy 1000 mg/kg body weight per day 500 mg/kg body weight per day [29, 30]
Balb/c mice 10 weeks Fatty liver 1500 mg/kg body weight per day NA [31]
Sprague–Dawley rats 12 weeks Periportal liver fibrosis 810 mg/kg body weight per day NA [32]
Fischer rats 103 weeks Reduced liver weight 1000 mg/kg body weight per day 500 mg/kg body weight per day [33]
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in rodents cannot be considered as adequate for risk 
assessment because it is not clear whether the research 
was conducted under generally accepted guidelines and 
because the test material was not properly described [35].
To summarize, a critical analysis of existing oral 
repeated dose studies in rodents reveals data gaps and 
uncertainties limiting their predictive value for the risk 
assessment of human dietary exposure. Some studies 
were based on poorly characterized particles in terms of 
composition, impurities or physico-chemical properties, 
and most reports lacked an assessment of particle size 
distribution.
Oral bioavailability and systemic distribution
Little is known on the intestinal absorption of nano-sized 
SAS particles and the potential to disseminate into tis-
sues. A limited systemic uptake following oral inges-
tion cannot be ruled out although none of the tested 
SAS particles were shown to bio-accumulate [19]. This 
is illustrated by a repeated dose kinetic study, in which 
rats were administered SAS particles via gavage at a low 
dose of 20 mg/kg body weight during 5 consecutive days 
[36, 37]. On the sixth day of the study, measurements by 
quadrupole inductively coupled plasma mass spectrome-
try (ICP-MS) revealed only slightly elevated silicon levels 
in liver and spleen. The gastrointestinal absorption after 
administration of SAS particles, estimated from these 
silicon measurements in tissues and not considering a 
concurrent excretion, ranged between 0.03 and 0.06 % of 
the total oral dose [38]. In another repeated dose study 
already presented above, rats were administered SAS 
particles via feed for 28  days, with continued adminis-
tration in the high-dose group for up to 84 days. Silicon 
contents were measured at days 29 and 84 by ICP-MS in 
liver, spleen, kidney, brain and testis. Conversion of the 
resulting silicon levels to assumed silica concentrations 
in tissues, again not considering concomitant excre-
tion processes, indicated an overall oral bioavailability of 
0.02  % or less [32]. The highest silica concentration (up 
to ~300  mg/kg tissue against a physiologic background 
below the limit of detection) was found in the spleen of 
SAS-exposed animals. So far, no SAS particles have been 
detected in mesenteric lymph nodes or any other organ 
after oral uptake and, therefore, it is not clear whether 
the observed silicon residues exist in a particulate form 
or rather in a dissolved state, for example as orthosilicic 
acid.
Another key issue that has not yet been investigated 
with regard to bioavailability and systemic distribution 
is the effect of biomolecules bound to nano-particles 
changing their surface properties [38]. In particular, SAS 
nano-particles are known to be decorated by proteins, for 
example fibrinogen or apolipoprotein A1, as soon as they 
get in contact with biological fluids [39]. The term “pro-
tein corona” was introduced to describe the attachment 
of plasma proteins to the surface of nano-particles [40, 
41]. One possible effect of this corona is that it mediates 
the uptake of nano-particles into cells and organs includ-
ing the liver, thus influencing bioavailability and tissue 
distribution [42].
Human exposure
To obtain realistic dietary exposure values for a European 
population, Dekkers and colleagues [18] selected food 
products from a local supermarket (ready-to-eat meals, 
soups, sauces, coffee creamers, pancake mixes, season-
ings and supplements) based on declarations for the 
presence of E 551. Next, the total silica concentration in 
these products was determined by inductively coupled 
plasma atomic emission spectrometry (ICP-AES). Then, 
dietary intake estimates of these products for the popu-
lation were calculated using a Dutch food consumption 
survey [43]. Based on estimated consumption and silica 
levels, the resulting daily dietary intake was 9.4 mg SAS 
particles per kg body weight. This total daily quantity 
includes all SAS particles regardless of their degree of 
aggregation or agglomeration. Hydrodynamic chroma-
tography with inductively coupled plasma mass spec-
trometry (HDC-ICPMS) showed that up to ~40 % of SAS 
particles detected in food products display an external 
diameter <200 nm [18].
The next question was whether the SAS particles 
in commercial food products would be destroyed in 
the digestive tract or rather withstand gastrointestinal 
Table 2 Outline of the chronic toxicity study with SAS particles carried out in rats
Summarized data from the oral chronic toxicity study in Fischer rats [33]. This table illustrates the relationship between body weight, feed intake and daily doses in the 
females of the highest dose group, where the feed was supplemented with 5 % (wt/wt) SAS particles. When corrected for the actual feed intake, the daily dose of SAS 
particles was between 1.8 and 2.0 g/kg body weight during most of the study period
Weeks of feeding
0 5 15 30 50 81 103
Body weight (g) 108 ± 6 174 ± 9 223 ± 11 253 ± 10 310 ± 18 364 ± 26 359 ± 56
Feed intake (g/day) 11.1 ± 0.4 10.4 ± 0.4 10.2 ± 0.5 11.9 ± 0.8 13.2 ± 0.8 12.7 ± 2.7
SAS intake (g/kg body weight per day) 3.2 2.3 2.0 1.9 1.8 1.8
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conditions. Using an in  vitro system mimicking human 
gastric digestion, it could be demonstrated that nano-
structured silica forms agglomerates under acidic condi-
tions resembling the milieu of the stomach. By switching 
the conditions to those imitating the subsequent intes-
tinal digestion stage, however, these large agglomerates 
disintegrate readily into nano-sized silica structures. In 
light of these in vitro findings, it was concluded that up 
to ~80 % of orally ingested SAS particles withstand gas-
tric dissolution and display a nano-sized range once they 
reach the intestinal lumen [44].
Inadequacies of existing risk assessments
Nano-particles are neither inherently toxic nor inher-
ently safe and possible adverse effects should be tested 
case-by-case. In principle, a standard assessment with 
risk =  hazard ×  exposure, which includes hazard iden-
tification, hazard characterization, exposure assessment 
and risk characterization, is applicable to nano-materials 
in food [21, 45, 46].
The United Kingdom Food Standards Agency Expert 
group on Vitamins and Minerals (EVM) performed an 
assessment of the oral safety of SAS particles, yielding a 
safe upper dietary level for daily consumption of 1500 mg 
SAS particles per day for adults [34]. This upper safety 
limit was calculated from the only available long-term 
toxicity study in rats [33], despite its limitations recently 
reiterated by the Scientific Committee on Consumer 
Safety [35]. The EVM experts noted that oral exposure to 
SAS particles for 103 consecutive weeks elicited effects 
on body weight and absolute liver weight (concerning the 
groups with a 2.5 and 5 % dietary inclusion rate). How-
ever, they attributed this outcome to possible nutritional 
imbalances, not adjusted in these two higher dose groups 
and considered unlikely to be relevant for humans. 
On this basis, the EVM group concluded that the no 
observed adverse effect level (NOAEL) is equivalent to 
the highest dose tested, i.e. 5 % SAS (wt/wt) in the diet. 
In the absence of further information or studies explain-
ing the reduction in body and liver weight, we advocate a 
more cautious approach by deriving from the same study 
a lower NOAEL equivalent to the 1.25 % inclusion rate, 
also in view of the emergence of liver hyperplastic nod-
ules and adrenal pheochromcytomas recorded in a few 
SAS-treated males but never in controls [33]. This more 
cautious interpretation is supported by a recent, above-
described study [32] revealing periportal liver fibrosis in 
SAS-exposed rats.
As indicated, the EVM expert group opted for a 
NOAEL of 5  % dietary inclusion and further estimated 
that this translates by default to a daily dose of 2.5 g/kg 
body weight. After introducing an uncertainty factor of 
100 (to adjust for inter-species as well as inter-individual 
variations in sensitivity), the derived safe upper level for 
lifetime daily consumption of SAS particles was 25 mg/
kg per day, equivalent to 1500  mg per day for a 60-kg 
adult. In terms of elemental silicon, the “safe” upper limit 
for daily consumption is 12 mg/kg body weight per day 
(equivalent to 700 mg for a 60-kg adult). In 2004, the Sci-
entific Panel on Dietetic Products, Nutrition and Aller-
gies (NDA Panel) at the European Food Safety Authority 
concluded for silicon that “there are no suitable data for 
dose—response for establishment of an upper level” [47]. 
In 2009, however, the Scientific Panel on Food Additives 
and Nutrient Sources added to Food (ANS Panel) took 
into consideration the risk assessment carried out by the 
EVM experts and adopted their proposed upper limit of 
1500 mg per day when assessing silicon dioxide as food 
additive [46]. It remains to be mentioned that default 
intake calculations made by translating a 5 % inclusion in 
the feed of rats to an assumed ingestion of 2.5 g/kg per 
day seem incorrect as the actual daily dose of SAS parti-
cles, determined from feed consumption in the high-dose 
group, was around 1.9 g/kg body weight during most of 
the study period (Table 2). Similarly, the lower inclusion 
rates of 1.25 and 2.5  % correspond to daily oral doses 
of around 0.5 and 1  g/kg, respectively. To summarize, 
several gaps in both study design and interpretation of 
results diminish the predictability of the only available 
long-term bioassays in rodents addressing the oral safety 
of SAS particles.
Potential for local effects in the gastrointestinal 
tract
Depending on the nature of identified hazards that raise 
concerns, the canonical risk characterization may need 
to be complemented with endpoints that are not rou-
tinely assessed in the toxicological evaluation of chemi-
cals. For example, a nano-Trojan horse hypothesis has 
previously been proposed in view of the observation 
that, in human lung epithelial cells exposed to Co3O4 or 
Mn3O4 nano-particles, the generation of reactive oxygen 
species (ROS) was higher than in controls exposed to 
an equivalent concentration of dissolved cobalt or man-
ganese salts [10]. It is equally conceivable that the bind-
ing of luminal antigens to SAS particles could aid their 
delivery to reactive cells of the gastrointestinal tract. In 
this respect, we note in particular that none of the above-
reviewed studies examined local effects on the lymphoid 
tissue of the gastrointestinal mucosa. Rather than causing 
ROS production, SAS particles have been implicated in 
the release of pro-inflammatory cytokines (see below).
Although the function of the immune system is to 
safeguard the host against invasive pathogens, the 
steady-state gastrointestinal tract is geared towards 
immune silencing or tolerance to avoid futile reactions 
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to innocuous food antigens and beneficial commensal 
microorganisms [48, 49]. Upon oral exposure, foreign 
particles encounter a single layer of mucous membrane 
lining the digestive tract. This large vulnerable surface is 
defended by the gut-associated lymphoid tissue, which 
consists of loosely organized clusters of lymphoid cells 
and more organized Peyer’s patches. Nano-particles 
including those made of silica are known to penetrate this 
lymphoid tissue underlying the epithelial barrier [50–53], 
where they may disrupt the critical balance between tol-
erance to harmless food constituents and commensals 
on the one hand and inflammatory reactions towards 
pathogens on the other hand [54, 55]. Specific analy-
ses of Peyer’s patches are not mentioned in the available 
sub-chronic and chronic toxicity studies in rodents and, 
therefore, it is not possible to ascertain whether delayed 
local effects on the gut-associated lymphoid system were 
adequately excluded.
Previous studies highlighted the fact that there is one 
critical site in which food-borne nano-particles accumu-
late during lifelong exposure, i.e., in “pigment cells” of the 
gut-associated lymphoid tissue where the earliest signs of 
inflammatory bowel disease (IBD) are noted (reviewed in 
[56–58]). This is a wide group of chronic conditions rang-
ing from Crohn’s disease (affecting all segments of the 
digestive tract) to ulcerative colitis (restricted to the large 
bowel, [59]). The main gatekeepers of tolerance in the 
intestinal system, as well as major mediators of adverse 
reactions like IBD, are specialized antigen-presenting 
cells known as dendritic cells [60]. They act as scavengers 
of foreign materials by extending branched and rapidly 
changing projections across the epithelial barrier into the 
gut lumen and taking up particles by endocytosis [61]. 
Particles are also delivered directly to dendritic cells after 
their passage through microfold cells (M-cells) in the 
intestinal mucosa. In this way, dendritic cells filter out a 
volume of up to 1500  µm3, which equals their own cell 
volume, per hour [62]. Unlike other antigen-presenting 
cells, dendritic cells constitutively express class II major 
histocompatibility complexes and, in response to patho-
gen recognition, display co-stimulatory surface glyco-
proteins and produce inflammatory cytokines. For these 
reasons, dendritic cells constitute potent activators of the 
innate immune system and also polyvalent drivers of T 
lymphocytes [63, 64]. As nano-particles are in the same 
size range as many proteins or common viruses, it is not 
surprising to find that, by virtue of their function in prob-
ing the environment for intruding insults, dendritic cells 
capture nano-particles in an efficient manner [65–67].
It was shown that endotoxin-activated dendritic 
cells release the potent pro-inflammatory cytokine 
interleukin-1β (IL-1β) upon incubation with SAS nano-
particles [68]. Mechanistically, this response has been 
linked to activation of the inflammasome complex, which 
in turn cleaves the pro-IL-1β precursor protein to release 
active IL-1β. In view of this finding, it will be of pivotal 
importance to determine how steady-state dendritic cells 
like those residing in the normal non-inflammatory intes-
tinal mucosa react to the presence of food-borne SAS 
particles. IBD has a multi-factorial origin with genetic 
susceptibility, gut microflora and a dysfunction of the 
mucosal immune system as main drivers [60]. Addition-
ally, various dietary factors have been implicated in the 
increasing incidence of IBD and several authors raised 
the concern that food-borne nano-particles may con-
tribute to initiating this chronic inflammatory disease 
[69–71]. Inadvertent stimulation of the immune system 
by nano-particles could trigger a reaction sequence that 
abrogates tolerance to food constituents and commensal 
bacteria and thereby favor immune-mediated conditions 
with the hallmarks of IBD (reviewed by [72]).
Conclusions
Previous and current controversies on hormone or anti-
biotic residues in food illustrate that nutrition is a highly 
emotional area in the public perception. The finding that 
SAS particles activate the inflammasome and, hence, are 
not biologically inert is intriguing because this type of 
nano-structured material has been employed since dec-
ades as food additive and is so far considered to be safe 
for consumers. Based on a critical review of existing oral 
toxicity studies, however, we consider that adverse effects 
from food-borne SAS particles cannot be excluded. 
Table  1 summarizes independent repeated dose stud-
ies that reached much the same conclusion with an 
oral NOAEL of 500  mg per kg body weight and a low-
est observed adverse effect level (LOAEL) in the range of 
810–1500  mg per kg body weight. Therefore, we advo-
cate a prudent approach by taking the oral NOAEL of 
500 mg/kg, based on body and liver weights in the 103-
week feeding study in rats, as point of departure for the 
risk assessment of SAS particles. This NOAEL is lower 
than previously proposed [34] but, as summarized in 
Table  1, is consistent with the outcome (liver atrophy) 
of a 8-week feeding study and the liver effects (peripor-
tal fibrosis) in a 12-week feeding study, both in rats, at 
daily doses of 810–1000 mg/kg body weight. By applying 
a default uncertainty factor of 100 (to adjust for inter-
species and inter-individual variations in sensitivity), this 
NOAEL would yield a safe upper level for the lifetime 
intake of SAS particles of 5 mg/kg body weight per day. 
The estimated consumption by a European population 
of 9.4 mg per kg body weight and day would, therefore, 
suggest that the dietary exposure to SAS particles should 
be reduced to remain, even with a worst case exposure 
scenario, below this newly proposed safety threshold of 
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5 mg/kg daily. Importantly, further studies are needed to 
investigate local effects of SAS particles in the gastroin-
testinal system, particularly on the gut-associated lym-
phoid tissue and embedded dendritic cells. In a broader 
perspective, mechanistic in vitro studies at different lev-
els of biological complexity are necessary to understand 
in depth how food-borne nano-particles may influence 
the delicate balance between immune tolerance and 
inflammatory responses that depends on the proper 
function of dendritic cells in the intestinal mucosa. This 
research direction is crucial to eventually address the 
concern that the higher occurrence of IBD may be in part 
a consequence of the lifelong ingestion of nano-sized or 
nano-structured food additives increasingly used in the 
modern diet.
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